Skip to content

Assessment of Music Experiences in Navigating Depression

Assessment of Music Experiences in Navigating Depression (AMEND)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06924892
Acronym
AMEND
Enrollment
84
Registered
2025-04-11
Start date
2023-04-05
Completion date
2025-03-30
Last updated
2025-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Depression, Music Assessment, Music Therapy, Anxiety

Brief summary

The study team sought to scientifically investigate strategic subsets of depressed individuals or people prone to or at-risk of depression through music experiences of individual, group, and blended supported contexts. Meetings with the study multi-disciplinary team, included member of the Carnegie Hall Weill Music Institute and University affiliates, where the study team gathered quantitative and qualitative data in individual and group forums, measuring disease process and levels of participation. Through tabulation of participatory options with standardized depression and resilience measurements, the study team studied how live music could alter depressive symptoms over time and/ or change negative influencers of mood, shift quality of life, and lead toward possibly enhanced disease trajectory outcomes.

Interventions

BEHAVIORALMusic therapy

Independent music therapy 45-minute sessions provided weekly for 3 months

OTHERWellness Concerts

Wellness Concerts provided at partner sites (Carnegie Hall Weill Music Institute, Cooper Union College, Third Street Music Settlement).

Sponsors

Carnegie Hall Weill Music Institute
CollaboratorUNKNOWN
Cooper Union College
CollaboratorUNKNOWN
Third Street Music Settlement
CollaboratorUNKNOWN
Icahn School of Medicine at Mount Sinai
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Masking description

Participants were provided options for various music study inclusions

Intervention model description

Music therapy or no intervention provided for all consented participants

Eligibility

Sex/Gender
ALL
Age
8 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Participants between the ages of 8-70 years with a clinical diagnosis of Major Depressive Disorder (MOD) who met the DSM-5 (2013) criteria for a Major Depressive Episode, and/or who identify themselves, or are identified by family, or referring clinicians as depressed, or are prone to depression * Depressive episodes and/or showing symptoms of mild to moderate depression intensity * Self-reported satisfactory bilateral hearing * English or Spanish language fluency sufficient to complete the interviews and questionnaires

Exclusion criteria

* Axis I diagnosis, aside from MOD, considered the primary diagnosis * Bipolar Disorder Type I or II, * Axis II diagnosis such as antisocial or borderline. * Arrhythmia, * Pacemaker * Prolapsed vertebral disc, and * Recent back or neck injuries.

Design outcomes

Primary

MeasureTime frameDescription
Connor-Davidson Resilience Scale (CD-RISC)end of study at 3 monthsThe Connor-Davidson Resilience Scale (CD-RISC) measures inherent resiliency. The 10-item instrument has high internal consistency. Each item consists of a 5-point Likert scale (scored from zero to four). Ranging from 0-40 with higher scores reflecting greater perceived resilience.
The Beck Depression Inventory Second Edition (BDI-II) scoreend of study at 3 monthsThe Beck Depression Inventory Second Edition (BDI-II) is a multiple-choice self-report inventory that assesses severity of depression. The BDI-II contains 21 items on a 4-point scale from 0 (symptom absent) to 3 (severe symptoms). The minimum score is 0 and the maximum score is 63, with a higher score indicating more severe depressive symptoms.
Child Depression Inventoryend of study at 3 monthsThe total score range 0 to 54 which is converted to a T-Score, higher score indicates more symptoms.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026